Recbio Technology (02179.HK)

Executive Summary

Jiangsu Recbio Technology Co., Ltd. is a China-based innovative vaccine company established in 2012, focusing on best-in-class vaccines for infectious diseases. The company's integrated technology platform combines novel adjuvant development, protein engineering, and immunological evaluation. Its pipeline includes lead candidates in Phase III clinical trials for HPV, shingles, and RSV vaccines. With a strong foothold in the Chinese vaccine market and a public listing on the Hong Kong Stock Exchange (ticker: 02179.HK), Recbio is poised to address significant unmet needs in infectious disease prevention. The company's core strength lies in its proprietary adjuvants and protein engineering capabilities, which have the potential to enhance vaccine efficacy and immunogenicity. As it advances its late-stage pipeline, Recbio represents a compelling opportunity in the global vaccine landscape, particularly in emerging markets. The successful development and commercialization of its lead candidates could generate substantial value, though the company faces competition from established players and regulatory hurdles.

Upcoming Catalysts (preview)

• Q4 2026Phase III data readout for HPV vaccine (RecPhage-HPV)70% success
• Q2 2026BLA submission for shingles vaccine (RecShing)65% success
• Q3 2026Phase II/III interim data for RSV vaccine (RecRSV)60% success